BioSpace News Archive

The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.

Sangamo and Pfizer will use the company’s ZFP-TFs to develop the treatments that are linked to mutations of the C9ORF72 gene, which can cause both ALS and FTLD.

The analyst identified Vertex and Alexion as his top two picks among large cap biotechs in 2018.

Neogen announced today that its revenues for the second quarter of its 2018 fiscal year, which ended Nov. 30, increased 12% to $101,817,000, from the previous year’s second quarter revenues of $90,717,000.

The newly formed board will be chaired by the former CEO of the ASCO, Dr. Allen Lichter, who is joined by Dr. Shaomeng Wang, Ascentage’s Co-founder and CSO, and the Warner-Lambert/Parke-Davis Professor in Medicine at the University of Michigan, among other internationally recognized clinical oncology researchers and specialists.

Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair’s intellectual property for the development of treprostinil prodrug formulations.

SPRIX Nasal Spray is a NSAID indicated for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level.

Merck will hold its fourth-quarter and full-year 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Friday, February 2.

Agenus announced new leadership appointments to enhance its team and advance combination clinical programs which will support its planned BLA filings in the second half of 2019 and in 2020.

The retirement will be effective after the topline data release from the ongoing MEDALIST and BELIEVE Phase 3 clinical trials with luspatercept, expected to occur in the middle of this year.